Shares of Humanigen, Inc. (NASDAQ:HGEN) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $29.83.
A number of equities analysts have issued reports on HGEN shares. Roth Capital raised their price target on shares of Humanigen from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, March 29th. JPMorgan Chase & Co. began coverage on shares of Humanigen in a research note on Tuesday, February 23rd. They set a “neutral” rating and a $21.00 price objective on the stock. Zacks Investment Research raised shares of Humanigen from a “sell” rating to a “hold” rating in a research note on Friday, March 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective (up previously from $34.00) on shares of Humanigen in a research note on Monday, April 19th.
In other news, major shareholder Bay Ltd. Nomis sold 9,700 shares of the firm’s stock in a transaction that occurred on Wednesday, February 17th. The shares were sold at an average price of $19.92, for a total transaction of $193,224.00. Following the sale, the insider now owns 5,845,470 shares of the company’s stock, valued at approximately $116,441,762.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 389,166 shares of company stock worth $7,274,705 in the last ninety days. Corporate insiders own 37.50% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in HGEN. Charles Schwab Investment Management Inc. acquired a new stake in Humanigen in the 4th quarter valued at $3,270,000. tru Independence LLC acquired a new stake in Humanigen in the 4th quarter valued at $2,700,000. BlackRock Inc. grew its stake in Humanigen by 12.8% in the 4th quarter. BlackRock Inc. now owns 790,602 shares of the company’s stock valued at $13,836,000 after acquiring an additional 89,662 shares during the period. Northern Trust Corp acquired a new stake in Humanigen in the 4th quarter valued at $1,295,000. Finally, CM Management LLC acquired a new stake in Humanigen in the 4th quarter valued at $700,000. 30.18% of the stock is currently owned by hedge funds and other institutional investors.
HGEN traded up $1.11 during trading on Tuesday, reaching $18.04. 1,229,194 shares of the company’s stock were exchanged, compared to its average volume of 2,320,318. Humanigen has a 1 year low of $3.90 and a 1 year high of $33.95. The company’s fifty day simple moving average is $16.68 and its 200-day simple moving average is $17.08.
Humanigen (NASDAQ:HGEN) last posted its quarterly earnings results on Tuesday, March 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.04. The business had revenue of $0.31 million for the quarter. As a group, analysts predict that Humanigen will post -2.13 EPS for the current fiscal year.
Humanigen, Inc, a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia.
Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.